Want to see FR:SIGHT full AI Analyst Report?
SIGHT Stock Chart & Stats
€0.08
<€0.01(0.12%)
At close: 4:00 PM EDT
€0.08
<€0.01(0.12%)
Day’s Range― - ―
52-Week Range€0.08 - €0.24
Previous CloseN/A
Volume185.13K
Average Volume (3M)616.46K
Market Cap
€19.15M
Enterprise Value€23.78M
Total Cash (Recent Filing)€2.42M
Total Debt (Recent Filing)€12.86M
Price to Earnings (P/E)―
Beta0.33
Next Earnings
Sep 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding235,044,330
10 Day Avg. Volume718,774
30 Day Avg. Volume616,456
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-0.62
Price to Sales (P/S)15482.52
P/FCF Ratio-1.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.08Price Target Upside0.00%
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.32
Revenue Forecast (FY)€10.50M
Bulls Say, Bears Say
Bulls Say
Focused Gene-therapy PipelineThe company’s pipeline targets mitochondrial dysfunction and retinal neurodegeneration with LUMEVOQ for LHON, addressing a high unmet need. This specialized, orphan-disease focus and gene-therapy expertise align with durable industry tailwinds and regulatory incentives, improving long-term commercialization prospects if clinical success continues.
Improving Cash Burn And Lower DebtReported reductions in debt and a meaningful improvement in operating cash burn in 2025 materially ease near-term funding pressure. Lower debt and reduced negative cash flow extend runway and increase optionality for partnering or staged financing, a durable improvement versus prior years if trends persist.
Lean Operating StructureA very small headcount indicates a lean cost base that can conserve cash and enable focused R&D outsourcing or partnerships. For a development-stage biotech, a compact structure can extend runway and permit targeted investment in pivotal programs, supporting operational resilience while funding is constrained.
Bears Say
Collapsed RevenueA near-total collapse in revenue undermines the firm's ability to self-fund development and signals no commercial scale. This structural revenue shortfall increases reliance on external capital or partners and reduces visibility on sustainable operations until meaningful recurring or licensing income is established.
Negative Shareholders' EquityPersistent negative equity reflects accumulated losses and solvency strain, limiting access to traditional credit and making leverage metrics less informative. This structural balance-sheet weakness increases the likelihood of dilutive financing and constrains strategic flexibility until profitability or recapitalization occurs.
Ongoing Operating Cash BurnConsistently negative operating cash flow indicates chronic cash burn despite recent improvement. Continued dependency on external funding creates durable execution and funding risk, as the company must secure financing or partnerships to support development and regulatory milestones absent sustained cash generation.
GenSight Biologics SA News
SIGHT FAQ
What was GenSight Biologics SA’s price range in the past 12 months?
GenSight Biologics SA lowest stock price was €0.07 and its highest was €0.24 in the past 12 months.
What is GenSight Biologics SA’s market cap?
GenSight Biologics SA’s market cap is €19.15M.
When is GenSight Biologics SA’s upcoming earnings report date?
GenSight Biologics SA’s upcoming earnings report date is Sep 29, 2026 which is in 55 days.
How were GenSight Biologics SA’s earnings last quarter?
GenSight Biologics SA released its earnings results on Mar 27, 2026. The company reported -€0.027 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.027.
Is GenSight Biologics SA overvalued?
According to Wall Street analysts GenSight Biologics SA’s price is currently same.
Does GenSight Biologics SA pay dividends?
GenSight Biologics SA does not currently pay dividends.
What is GenSight Biologics SA’s EPS estimate?
GenSight Biologics SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GenSight Biologics SA have?
GenSight Biologics SA has 235,044,330 shares outstanding.
What happened to GenSight Biologics SA’s price movement after its last earnings report?
GenSight Biologics SA reported an EPS of -€0.027 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.409%.
Which hedge fund is a major shareholder of GenSight Biologics SA?
Currently, no hedge funds are holding shares in FR:SIGHT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GenSight Biologics SA
GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous system. Their therapeutic development leverages cutting-edge gene therapy platforms, specifically those involving mitochondrial targeting sequences and optogenetics. The company's leading drug candidate, LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, is currently undergoing Phase III clinical evaluation for treating Leber hereditary optic neuropathy (LHON) caused by a specific ND4 gene mutation. Another significant program, GS030, is engaged in Phase I/II clinical trials for retinitis pigmentosa and is also in the preclinical phase for dry age-related macular degeneration. Furthermore, GenSight Biologics is developing additional preclinical-stage programs aimed at various ophthalmic and neurodegenerative disorders. The company was founded in 2012 and maintains its headquarters in Paris, France.
SIGHT Stock 12 Month Forecast
Average Price Target
€0.08
▲(0.00% Upside)